The Stock2Me Podcast

Stock2Me’s latest podcast features Rod Turner, CEO and Founder of Manhattan Street Capital, the premier growth capital platform for midsize and startup companies.

Throughout the interview, Turner discussed his professional background – from his time as an engineer to his successful track record as an entrepreneur – before examining why he founded Manhattan Street Capital.

“In March 2015, Reg A+ was announced, and it went effective in late June. When I read the regulation, I was shocked and impressed by how well-written it is,” Turner said. “Having raised money and invested money in startup companies over so many years and such a large portion of my business life, I’m aware of how the current lending climate for capital raising was limiting lots of great companies that could otherwise justify and deploy growth capital successfully and make public offerings successfully. Reg A+ provided a phenomenally great way to up the ante and improve the situation… The timing was great, so I decided to found Manhattan Street Capital in May 2015 – about a month before Reg A+ became effective. We were the first Reg A+-focused offering platform in what is essentially crowd investing. I believe that Reg A+, when it hits stride, will be a very, very large segment of the capital-raising industry.”

Join IBN’s Stuart Smith and Rod Turner to learn more about the rapid growth of the Reg A+ space and the trends guiding the online capital formation business in 2023.

Stock2Me’s latest podcast features Rod Turner, CEO and Founder of Manhattan Street Capital, the premier growth capital platform for midsize and startup companies.

Throughout the interview, Turner discussed his professional background – from his time as an engineer to his successful track record as an entrepreneur – before examining why he founded Manhattan Street Capital.

“In March 2015, Reg A+ was announced, and it went effective in late June. When I read the regulation, I was shocked and impressed by how well-written it is,” Turner said. “Having raised money and invested money in startup companies over so many years and such a large portion of my business life, I’m aware of how the current lending climate for capital raising was limiting lots of great companies that could otherwise justify and deploy growth capital successfully and make public offerings successfully. Reg A+ provided a phenomenally great way to up the ante and improve the situation… The timing was great, so I decided to found Manhattan Street Capital in May 2015 – about a month before Reg A+ became effective. We were the first Reg A+-focused offering platform in what is essentially crowd investing. I believe that Reg A+, when it hits stride, will be a very, very large segment of the capital-raising industry.”

Join IBN’s Stuart Smith and Rod Turner to learn more about the rapid growth of the Reg A+ space and the trends guiding the online capital formation business in 2023.

Stock2Me’s latest podcast features David Jemmett, CEO and Founder of Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) (“CISO Global” or the “Company”), an industry leader in cybersecurity and compliance services.

Throughout the interview, Jemmett discussed the core values and mission of Cerberus Sentinel.

“Cerberus Sentinel was founded at a period of time when there were 800,000 job openings in cyber. There’s been a zero jobless rate since 2011. This year alone there are four million job openings [in cyber] globally,” Jemmett said. “A lot of my friends and coworkers have started cybersecurity companies in the past, but they were very verticalized – training, gap analysis, compliance or SOC services… At Cerberus Sentinel, we help our clients find their cyber issues, remediate them and keep on top of them. Cybersecurity is a journey; it’s not an endpoint. We’ll continue to work on the evolving threat matrix with our customers to help them keep improving.”

Join IBN’s Stuart Smith and David Jemmett to learn more about the company’s unique offerings in the cyber space and how they differentiate Cerberus Sentinel from the competition.

Stock2Me’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. 

In this podcast episode, Reichman introduced the history of BiondVax leading up to his appointment as CEO before discussing the company’s recent development efforts focused on innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets. 

“BiondVax is a biotechnology company focused on research and development. It is located in Jerusalem, Israel. It was founded about 17 years ago by an entrepreneur who took a spinoff from the Weizmann Institute of Science in Israel with a mission to develop a universal influenza vaccine,” Reichman said. “The vaccine was developed in the laboratory of Professor Ruth Arnon, a world-renowned professor and researcher mostly known for co-developing Copaxone, the multiple sclerosis drug marketed by Teva Pharmaceuticals. The universal influenza vaccine was then developed by BiondVax throughout the next 15 years, covering Preclinical, Phase I and multiple Phase II trials before ending up with a Phase III – the biggest Phase III ever conducted by an Israeli pharma company, with 12,400 participants spanning seven countries. 

The latest installment of The Stock2Me Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. 

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine 

Stock2Me’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. 

In this podcast episode, Reichman introduced the history of BiondVax leading up to his appointment as CEO before discussing the company’s recent development efforts focused on innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets. 

“BiondVax is a biotechnology company focused on research and development. It is located in Jerusalem, Israel. It was founded about 17 years ago by an entrepreneur who took a spinoff from the Weizmann Institute of Science in Israel with a mission to develop a universal influenza vaccine,” Reichman said. “The vaccine was developed in the laboratory of Professor Ruth Arnon, a world-renowned professor and researcher mostly known for co-developing Copaxone, the multiple sclerosis drug marketed by Teva Pharmaceuticals. The universal influenza vaccine was then developed by BiondVax throughout the next 15 years, covering Preclinical, Phase I and multiple Phase II trials before ending up with a Phase III – the biggest Phase III ever conducted by an Israeli pharma company, with 12,400 participants spanning seven countries. 

The latest installment of The Stock2Me Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. 

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine 

Stock2Me’s latest podcast features two-time Olympic gold medalist Abby Wambach speaking on behalf of Odyssey Health Inc. (OTC: ODYY), a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy.

Throughout the interview, Wambach discussed her soccer career and how concerns about brain health led her to team with Odyssey Health.

“I had a unique, long career playing for the Women’s National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I’ve been retired for six years), I’ve had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.”

Stock2Me’s latest podcast features two-time Olympic gold medalist Abby Wambach speaking on behalf of Odyssey Health Inc. (OTC: ODYY), a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy.

Throughout the interview, Wambach discussed her soccer career and how concerns about brain health led her to team with Odyssey Health.

“I had a unique, long career playing for the Women’s National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I’ve been retired for six years), I’ve had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.”

Stock2Me’s latest podcast features the return of Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications. 

Throughout the interview, Clifford discussed FuelPositive’s rapid development throughout 2021 and early in 2022 as it works to change the landscape surrounding ammonia production, with a focus on sustainability. 

“2021 was a kick-off year for us. It was incredible the amount of growth that we were able to attain during the year,” Clifford said. “If you go back to January 2021, we formally became FuelPositive. A couple of months later, we acquired our core technology, which of course is a modular and scalable green ammonia production technology. We’re now right in the process of initial commercialization of demonstration systems… Our focus is very much on looking at technologies that are ready to commercialize today. We’re building now as we speak upon our core technology with add-on and very accretive intellectual property that is improving dramatically upon our core systems.” 

Stock2Me’s latest podcast features the return of Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications. 

Throughout the interview, Clifford discussed FuelPositive’s rapid development throughout 2021 and early in 2022 as it works to change the landscape surrounding ammonia production, with a focus on sustainability. 

“2021 was a kick-off year for us. It was incredible the amount of growth that we were able to attain during the year,” Clifford said. “If you go back to January 2021, we formally became FuelPositive. A couple of months later, we acquired our core technology, which of course is a modular and scalable green ammonia production technology. We’re now right in the process of initial commercialization of demonstration systems… Our focus is very much on looking at technologies that are ready to commercialize today. We’re building now as we speak upon our core technology with add-on and very accretive intellectual property that is improving dramatically upon our core systems.” 

Stock2Me’s latest podcast features Chris Bunka, Chairman & CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms.

To begin the interview, Bunka provided a summary of Lexaria’s business model, which is focused on leveraging the company’s proprietary DehydraTECH™ drug delivery technology.

“[Lexaria has] developed a drug delivery technology that’s quite unique,” Bunka said. “What our technology does is it allows people to swallow any number of various drugs or active pharmaceutical ingredients (APIs) and basically allow a larger proportion of the drug to… get into the bloodstream and reach the site of action. That is what our technology is focused on, and, because we’re so good at it, we’re actually seeing applications in all sorts of different business sectors, be it cannabidiol, nicotine for oral delivery, antiviral drugs and others… We do not sell any drugs ourselves, but we do sell or ‘rent’ our technology.”

Stock2Me’s latest podcast features Chris Bunka, Chairman & CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms.

To begin the interview, Bunka provided a summary of Lexaria’s business model, which is focused on leveraging the company’s proprietary DehydraTECH™ drug delivery technology.

“[Lexaria has] developed a drug delivery technology that’s quite unique,” Bunka said. “What our technology does is it allows people to swallow any number of various drugs or active pharmaceutical ingredients (APIs) and basically allow a larger proportion of the drug to… get into the bloodstream and reach the site of action. That is what our technology is focused on, and, because we’re so good at it, we’re actually seeing applications in all sorts of different business sectors, be it cannabidiol, nicotine for oral delivery, antiviral drugs and others… We do not sell any drugs ourselves, but we do sell or ‘rent’ our technology.”

Stock2Me’s latest podcast features Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on manufacturing, licensing, partnership and acquisition opportunities building upon various technological achievements.

Throughout the interview, Clifford discussed FuelPositive’s innovative carbon-free ammonia technology and its potential to change the energy landscape, both across Canada and around the world.

“We have purchased, back in April 2021, a cutting-edge technology that is designed to produce carbon-free ammonia, or carbon-free NH3 as it’s also known, in a proprietary, environmentally sound and economically viable process,” Clifford said. “This technology… allows for the production of ammonia in a scalable and modular fashion. That means that we can set up our systems to produce carbon-free ammonia where it’s needed and when it’s needed, which is a very, very significant departure from the way that ammonia is produced today… Ammonia today… is one of the most carbon-intense processes on the planet. Our system is entirely carbon-free.”

Stock2Me’s latest podcast features Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on manufacturing, licensing, partnership and acquisition opportunities building upon various technological achievements.

Throughout the interview, Clifford discussed FuelPositive’s innovative carbon-free ammonia technology and its potential to change the energy landscape, both across Canada and around the world.

“We have purchased, back in April 2021, a cutting-edge technology that is designed to produce carbon-free ammonia, or carbon-free NH3 as it’s also known, in a proprietary, environmentally sound and economically viable process,” Clifford said. “This technology… allows for the production of ammonia in a scalable and modular fashion. That means that we can set up our systems to produce carbon-free ammonia where it’s needed and when it’s needed, which is a very, very significant departure from the way that ammonia is produced today… Ammonia today… is one of the most carbon-intense processes on the planet. Our system is entirely carbon-free.”

Stock2Me’s latest podcast features Dr. Art Dawson, U.S. Business Manager of Save Foods (NASDAQ: SVFD), an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables.

Throughout the interview, Dawson discussed Save Foods’ innovative technology and examined how its products are helping combat excessive waste in the fresh produce industry.

“The most important thing to know is that Save Foods has successfully completed the development and has also begun to market natural, eco-friendly solutions for fresh produce,” Dawson said. “These solutions are used in the process of protecting fresh fruits and vegetables, and, therefore, they’re an important part of the economic scheme of the fresh produce value chain. This is because the products themselves contribute to the extension of shelf life within that value chain. They are also used simultaneously to ensure food safety and to ensure compliance with the current U.S. Food Safety Modernization Act.”

Stock2Me’s latest podcast features Dr. Art Dawson, U.S. Business Manager of Save Foods (NASDAQ: SVFD), an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables.

Throughout the interview, Dawson discussed Save Foods’ innovative technology and examined how its products are helping combat excessive waste in the fresh produce industry.

“The most important thing to know is that Save Foods has successfully completed the development and has also begun to market natural, eco-friendly solutions for fresh produce,” Dawson said. “These solutions are used in the process of protecting fresh fruits and vegetables, and, therefore, they’re an important part of the economic scheme of the fresh produce value chain. This is because the products themselves contribute to the extension of shelf life within that value chain. They are also used simultaneously to ensure food safety and to ensure compliance with the current U.S. Food Safety Modernization Act.”

Stock2Me’s latest podcast features Shan Sawant, Director of Communications for AmpliTech Group Inc. (NASDAQ: AMPG), a company engaged in the design, development and manufacture of custom radio frequency (RF) components for the commercial, SATCOM, space and military markets.

Throughout the interview, Sawant discussed AmpliTech’s business model, offering an overview of the company’s proven, decades-long track record of providing vital radio frequency components to an impressive list of clients.

“AmpliTech provides high-quality radio frequency (RF) components that allow for high performance, low noise wireless connections in devices and systems,” Sawant said. “As we know, today, virtually every mobile device requires a wireless signal of some kind, and systems are beginning to need to process more data than ever before. That creates an unprecedented demand for signal bandwidth to move applications and data in a fast and highly reliable way.”

Stock2Me’s latest podcast features Shan Sawant, Director of Communications for AmpliTech Group Inc. (NASDAQ: AMPG), a company engaged in the design, development and manufacture of custom radio frequency (RF) components for the commercial, SATCOM, space and military markets.

Throughout the interview, Sawant discussed AmpliTech’s business model, offering an overview of the company’s proven, decades-long track record of providing vital radio frequency components to an impressive list of clients.

“AmpliTech provides high-quality radio frequency (RF) components that allow for high performance, low noise wireless connections in devices and systems,” Sawant said. “As we know, today, virtually every mobile device requires a wireless signal of some kind, and systems are beginning to need to process more data than ever before. That creates an unprecedented demand for signal bandwidth to move applications and data in a fast and highly reliable way.”

Stock2Me’s latest podcast features Allan Jones, President of Emaginos Inc., which recently submitted a U.S. patent application for its EdManage analytics platform for public education.

Throughout the interview, Jones discussed how the EdManage program was developed, how it works and the benefits it provides for students.

“A few years ago, our Director of Education, Dr. Keith Larick, was school superintendent in Tracy, California. He gave three teachers a clean slate and one year to design the best possible school based on proven best education practices,” Jones said. “They did that, and they’ve created an amazing program that’s been very effective for years. What we’re trying to do is take their model and make it available to other schools. That’s our goal – to transform schools to this very successful model used at the Tracy Learning Center.”

Stock2Me’s latest podcast features Allan Jones, President of Emaginos Inc., which recently submitted a U.S. patent application for its EdManage analytics platform for public education.

Throughout the interview, Jones discussed how the EdManage program was developed, how it works and the benefits it provides for students.

“A few years ago, our Director of Education, Dr. Keith Larick, was school superintendent in Tracy, California. He gave three teachers a clean slate and one year to design the best possible school based on proven best education practices,” Jones said. “They did that, and they’ve created an amazing program that’s been very effective for years. What we’re trying to do is take their model and make it available to other schools. That’s our goal – to transform schools to this very successful model used at the Tracy Learning Center.”

Stock2Me’s latest podcast features Greg McKee, Chairman and CEO of Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing treatments, primarily psychedelics like psilocybin, for diseases with unmet medical needs.

Throughout the interview, McKee discussed the company’s prospective patients and targeted ailments, the need for innovation in the psychedelics space and Tryp’s planned human clinical trials later this year.

“We’re here fundamentally to help patients. We’re also very interested in bringing new therapies to these patients. All these indications that we’re working in – specifically fibromyalgia, phantom limb syndrome and complex regional pain syndrome, and potentially others such as tinnitus, cluster headaches, TMJ and others – all these subcategories of chronic pain are areas where there is significant unmet medical need,” McKee said. “In other words, situations where patients aren’t properly served. We know that new chemistries and new solutions need to be brought to the table. There needs to be a broader set of tools that physicians can use to treat these patients.”